Miostat (Carbachol)

Carbachol, the active ingredient in Miostat, is a cholinergic agonist presented as an ophthalmic solution for intraocular use. It is employed to induce pupil constriction and facilitate aqueous humor outflow in ocular procedures and certain glaucoma conditions.

GNH USA supplies Miostat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Carbachol, marketed as Miostat, acts on the cholinergic pathway to produce miosis and lower intraocular pressure in several ophthalmic conditions. - Intra‑operative miosis: provides controlled pupil constriction during cataract and anterior segment surgery. - Acute angle‑closure glaucoma: helps open the trabecular meshwork to reduce intraocular pressure. - Post‑operative ocular hypertension: promotes aqueous outflow to prevent pressure spikes after eye surgery.

Carbachol may cause ocular and systemic reactions that vary in frequency and severity.

Common Side Effects: - Blurred vision: transient loss of visual clarity after instillation. - Eye pain or discomfort: mild irritation at the application site. - Headache: occasional mild headache following ocular exposure. - Transient rise in intraocular pressure: brief elevation before pressure reduction. - Conjunctival hyperemia: redness of the eye. - Excessive tearing: increased lacrimation.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or anaphylaxis requiring immediate medical attention. - Persistent mydriasis: prolonged pupil dilation leading to photophobia. - Corneal edema: swelling of the cornea that may impair vision. - Systemic cholinergic effects: bradycardia, bronchospasm, or gastrointestinal cramps in susceptible patients.

Prior to using Miostat, clinicians should evaluate patient‑specific factors and follow safe handling practices. - Assess intraocular pressure: ensure baseline measurements are documented. - Avoid in patients with known hypersensitivity to carbachol or formulation excipients. - Use with caution in individuals with asthma or chronic obstructive pulmonary disease. - Monitor for systemic cholinergic signs, especially in patients on other cholinergic agents. - Store at room temperature: keep in the original container, protect from light and moisture.

Carbachol may interact with other ocular or systemic agents, altering its efficacy or safety profile.

Major Interactions (Avoid): - Systemic anticholinergics (e.g., atropine): may antagonize miotic effect. - Beta‑blocker eye drops: combined use can increase risk of bradycardia if systemic absorption occurs. - Other miotic agents: additive pupil constriction may lead to excessive miosis.

Moderate Interactions (Monitor Closely): - Systemic cholinesterase inhibitors: may potentiate cholinergic activity and increase side‑effect risk. - Topical anesthetics: can modify ocular absorption of carbachol. - Systemic sympathomimetics: may counteract the desired intraocular pressure‑lowering effect.